Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG MIX 70 30 versus NOVOLOG PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG MIX 70 30 versus NOVOLOG PENFILL.
NOVOLOG MIX 70/30 vs NOVOLOG PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphasic insulin analog combining rapid-acting insulin aspart and intermediate-acting protamine-crystallized insulin aspart, which lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production.
Insulin aspart is a rapid-acting recombinant human insulin analog. It lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, promoting glucose uptake, and inhibiting hepatic glucose production via glycogenolysis and gluconeogenesis.
Subcutaneous injection only. Typical total daily insulin dose ranges from 0.5 to 1.0 units/kg/day divided into two or three injections. Administer twice daily, with each dose given within 15 minutes before meals. Dose individualization based on glycemic targets and previous insulin regimen is required.
Subcutaneous injection: 0.5-1 unit/kg/day divided into multiple doses (e.g., basal-bolus regimen). Individualized based on glucose monitoring.
None Documented
None Documented
Insulin aspart (free component): ~1-2 hours; protamine-crystallized component: ~8-10 hours. Clinical context: Duration of action up to 24 hours due to the intermediate-acting component.
~5-7 minutes (free insulin aspart); clinical effect duration correlates with SC absorption half-life ~1-2 hours
Renal: 30-80% of dose excreted unchanged in urine for insulin aspart; for protamine-crystallized component, metabolism and renal elimination also occur. Biliary/fecal: Minor.
Renal: 60-80% as metabolites; unchanged drug excreted minimally. Fecal: <10%
Category C
Category C
Insulin Analog
Insulin Analog